Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleylacetoacetate SCHEMBL380205 | 1.00 | TSHR (0.45) | TSHRTP53EGLN1EGLN3LDHA | |
| Maleylacetoacetate SCHEMBL187565 | 1.00 | TSHR (0.45) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL2780998 | 0.87 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL2780997 | 0.87 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL1225122 | 0.87 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL12568561 | 0.84 | TSHR (0.64) | TSHRTP53EGLN1EGLN3HCAR2 | |
| SCHEMBL6916408 | 0.78 | LDHA (0.36) | TSHREGLN1LDHASRRKDM4E | |
| Maleic Acid SCHEMBL1038087 | 0.78 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA | |
| Fumaric Acid SCHEMBL28422912 | 0.78 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA | |
| Fumaric Acid SCHEMBL1038089 | 0.78 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162977-B2 | Blocked polyisocyanate crosslinking agent, its preparation method and a coating composition comprising the same | BASF COATINGS GMBH (DE) | 2024-12-10 | — | — | US | claimed |
| WO-2024177860-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2024-08-29 | — | — | WO | claimed |
| EP-4228424-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2023-08-23 | — | — | EP | claimed |
| CN-116390651-A | Methods of modulating gastrointestinal metabolites | 帝斯曼知识产权资产管理有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-20220389153-A1 | A BLOCKED POLYISOCYANATE CROSSLINKING AGENT, ITS PREPARATION METHOD AND A COATING COMPOSITION COMPRISING THE SAME | BASF COATINGS GMBH (DE) | 2022-12-08 | — | — | US | claimed |
| EP-4058500-A1 | A BLOCKED POLYISOCYANATE CROSSLINKING AGENT, ITS PREPARATION METHOD AND A COATING COMPOSITION COMPRISING THE SAME | BASF Coatings GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| CN-114729100-A | Blocked polyisocyanate crosslinkers, process for their preparation and coating compositions comprising the crosslinkers | 巴斯夫涂料有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022079238-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-21 | — | — | WO | claimed |
| WO-2021094237-A1 | A BLOCKED POLYISOCYANATE CROSSLINKING AGENT, ITS PREPARATION METHOD AND A COATING COMPOSITION COMPRISING THE SAME | BASF COATINGS GMBH (DE) | 2021-05-20 | — | — | WO | claimed |
| US-20190285632-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | EXCISION BIOTHERAPEUTICS, INC. (US) | 2019-09-19 | — | — | US | claimed |
| EP-3510148-A1 | HIV CLINICAL PLAN | Excision Biotherapeutics, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190194652-A1 | HIV CLINICAL PLAN | EXCISION BIOTHERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | claimed |
| EP-3465213-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | Excision Biotherapeutics, Inc. (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2018049372-A1 | HIV CLINICAL PLAN | EXCISION BIOTHERAPEUTICS INC (US) | 2018-03-15 | — | — | WO | claimed |
| WO-2017205460-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | EXCISION BIOTHERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | claimed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12559784-B2 | In chemico test for toxicity | LEBRUN LABS LLC (US) | 2026-02-24 | — | — | US | disclosed |
| EP-1583966-A2 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE USING 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050037946-A1 | Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419 | MILLENNIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004063340-A2 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE USING 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559784-B2 | In chemico test for toxicity | ALPP, ALPI, CUTA | TSHR 556/4885TP53 2462/4885EGLN1 4403/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | TSHR 1704/4885TP53 2128/4885EGLN1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.